Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $281,097.18 in Stock

Posted by Jeff Wilder on Oct 11th, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 10,218 shares of the stock in a transaction on Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $281,097.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $34,937.70.
On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00.
On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.53, for a total value of $27,282.23.
On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.
On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total value of $75,210.00.

Enliven Therapeutics Price Performance

ELVN opened at $26.97 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -13.97 and a beta of 1.10. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $28.62. The company has a fifty day moving average price of $23.34 and a 200-day moving average price of $22.22.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Get Our Latest Stock Analysis on ELVN

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ELVN. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the third quarter valued at approximately $256,000. The Manufacturers Life Insurance Company bought a new position in shares of Enliven Therapeutics in the 2nd quarter worth $322,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at $4,489,000. First Turn Management LLC purchased a new stake in Enliven Therapeutics during the second quarter valued at about $9,657,000. Finally, Nicholas Investment Partners LP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.